Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age

BACKGROUND: Hizentra® (IGSC 20 %) is a 20 % liquid IgG product approved for subcutaneous administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD). There is limited information about the use of IGSC 20 % in very young children including those les...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Niraj C., Gallagher, Joel L., Ochs, Hans D., Atkinson, Thomas Prescott, Wahlstrom, Justin, Dorsey, Morna, Bonilla, Francisco A., Heimall, Jennifer, Kobrynski, Lisa, Morris, David, Haddad, Elie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572047/
https://www.ncbi.nlm.nih.gov/pubmed/26336818
http://dx.doi.org/10.1007/s10875-015-0190-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572047/
https://www.ncbi.nlm.nih.gov/pubmed/26336818
http://dx.doi.org/10.1007/s10875-015-0190-0

Ejemplares similares